about
Acellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenPharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults: Systematic Review and Meta-AnalysisMaintaining the momentum: key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemicPandemic influenza in Canadian children: a summary of hospitalized pediatric cases.Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.Strategies for successful rapid trials of influenza vaccine.Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009.A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trialReducing the pain of childhood vaccination: an evidence-based clinical practice guideline (summary).Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline.Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation.Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data.Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Thrombocytopenia after immunization of Canadian children, 1992 to 2001.Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety.A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Postvaccination thrombocytopenia in Canada.Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection.Childhood immunization rates in Canada are too low: UNICEF.Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.Implementation of a universal rotavirus vaccination program: comparison of two delivery systems.Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic networkImmunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Challenges to immunization: the experiences of homeless youth.Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
P50
Q24193554-2390A9E9-6E55-4B5D-8BF0-49F2D4086D2EQ24201103-326AB999-3262-416C-869B-1EBD8970FFF7Q24234899-8DB427BB-4491-4CD6-8AE7-10A44AEB4DF1Q24243261-FE03D2E8-CAE9-47CF-B8DD-8FA09ECA8D0DQ26800959-CBCC85B9-1CFE-4DE5-9B1F-BD44AD6324ECQ30371626-4F59742E-EB26-4342-9871-7EC00B560A10Q30386139-1A13BBC5-A90E-405A-96FC-C4ED8F1CD935Q30397802-7C968877-7F65-499D-9AD1-D543E2E26ECDQ30405196-434EC2E6-5337-46D1-B92B-2EE0B13CD7FDQ30406834-208F89D6-DF18-4526-90C0-E75466309228Q30414902-38133250-CD24-48F4-9B59-910AB33F7B20Q30420770-31D1BE6F-1A83-466E-AF29-4E96E3852265Q30422975-C9BAA80B-9143-4D78-9EF2-A65DD187D88AQ30426236-588FF06C-88BC-4A48-BF17-BEDA6FC1210BQ30429170-6A88FE2C-662D-4C60-909B-7C1EA7CF64FFQ30497650-06D4B722-522C-4D96-8B0F-A31144E62955Q30497652-BE6555A4-8A3C-4076-ABE3-40C43C2EF088Q30540817-529C8528-0ABA-41B1-95A2-D851FB3FB082Q30890127-1FCB135D-5B25-4927-A2F0-0FFB5BA181EAQ30890134-1B268F64-BBD6-43DA-BA64-29BB8B4237E6Q31114165-0B51720A-B539-46D6-930E-BC5EC3489DE7Q31114324-BB92B6F5-19FC-4D31-8A06-363809B00A9EQ31114573-654CFAB8-4872-412F-8A7E-6DA917A6D6DCQ31114574-D3C1F86A-25DC-48DA-AB96-3639D969890EQ31114967-BDF50389-C2C2-4B80-A07D-E8CFA95B3407Q33346534-B9877962-008D-4DC9-B802-1E7DDE670C42Q33349477-C53A2970-07C4-4401-B412-F551130F6D03Q33379317-50F1AD3F-2EDD-4B29-B632-602505E6A1C0Q33388293-D183340A-E93D-4528-8B40-1C476D992613Q33593690-5C673F32-BFC4-4D8D-81DF-051018B66FA3Q33642880-85C0E103-9BE8-4DA4-96A2-D3C5731E17BEQ33713522-287783AE-7D79-4055-BF6A-5568011289EEQ33818337-A4BFC7EA-F3B1-40D4-B157-3F7D54D128B5Q33879545-6DF7BAA1-E626-41AA-9EC3-8EE30600B614Q34059015-37325972-DE62-42AC-A726-2BBBA66B2301Q34196755-6DD718EC-005C-4A6F-85F7-EEF722FD874DQ34238443-7E38DC0D-952F-4F8F-ADD8-1F84D73FE3B5Q34240937-2AA1F83D-FB41-4B13-96D9-AEFA5C4BDFB8Q34262409-FFE3FBBF-756E-431A-B252-4661C83221C6Q34342056-47552B12-4596-4BEA-BA27-9F81959CCD33
P50
name
Scott A Halperin
@ast
Scott A Halperin
@en
Scott A Halperin
@nl
type
label
Scott A Halperin
@ast
Scott A Halperin
@en
Scott A Halperin
@nl
prefLabel
Scott A Halperin
@ast
Scott A Halperin
@en
Scott A Halperin
@nl